Investigational Drug Information for Buparlisib
✉ Email this page to a colleague
What is the drug development status for Buparlisib?
Buparlisib is an investigational drug.
There have been 40 clinical trials for Buparlisib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 12th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Summary for Buparlisib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,351 |
| WIPO Patent Applications | 1,027 |
| Japanese Patent Applications | 275 |
| Clinical Trial Progress | Phase 3 (2020-12-12) |
| Vendors | 66 |
Recent Clinical Trials for Buparlisib
| Title | Sponsor | Phase |
|---|---|---|
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | Adlai Nortye Biopharma Co., Ltd. | Phase 3 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Janssen Scientific Affairs, LLC | Phase 1 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Novartis Pharmaceuticals | Phase 1 |
Clinical Trial Summary for Buparlisib
Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib
US Patents for Buparlisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
